Jazz Pharmaceuticals Ireland Ltd. has identified compounds acting as GTPase KRAS and its mutant inhibitors reported to be useful for the treatment of cancer.

Insmed Inc. has synthesized cathepsin C (dipeptidyl peptidase I) inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, asthma, cancer, chronic rhinosinusitis, heart failure, inflammatory bowel disease, psoriasis and thrombosis, among others.

Certa Therapeutics Pty Ltd. has disclosed ovarian cancer G-protein coupled receptor 1 (GPR68; OGR1) antagonists reported to be useful for the treatment of cancer, inflammation and fibrosis.

Zhejiang Bolaatu Medical Technology Co. Ltd. has described glucocorticoid receptor (GR) agonists reported to be useful for the treatment of asthma.

UCB SA has divulged compounds acting as NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of inflammation, injury, neurodegeneration, and eye, autoimmune and neurological disorders, among others.

Incyte Corp. has identified Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of inflammatory disorders.

Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has synthesized Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.

Nanjing Tian Yin Jian Hua Pharma Tech Co. Ltd. has disclosed receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, multiple sclerosis, psoriasis, rheumatoid arthritis, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), gout, inflammatory bowel and Alzheimer’s disease, among others.

Chengdu Chipscreen Pharmaceutical Ltd. has described ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.

Retune Pharma Inc. has divulged plasma kallikrein (KLKB1) inhibitors reported to be useful for the treatment of hereditary angioedema.